Literature DB >> 1512244

Protein sequence and mass spectrometric analyses of tau in the Alzheimer's disease brain.

M Hasegawa1, M Morishima-Kawashima, K Takio, M Suzuki, K Titani, Y Ihara.   

Abstract

Tau with unusually slow mobilities in sodium dodecyl sulfate-polyacrylamide gel electrophoresis was purified from the Sarkosyl-insoluble pellet of Alzheimer's disease brain homogenates. Such species of tau (PHF-tau) are considered to construct the framework of the sodium dodecyl sulfate-soluble form of paired helical filaments (PHF). Detailed comparison of peptide maps of PHF-tau and normal tau before and after dephosphorylation pointed to three anomalously eluted peaks which contained abnormally phosphorylated peptides, residues 191-225, 226-240, 260-267, and 386-438, according to the numbering of the longest tau isoform (Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., and Crowther, R. A. (1989) Neuron 3, 519-526). Protein sequence and mass spectrometric analyses localized Thr-231 and Ser-235 as the abnormal phosphorylation sites and further indicated that each tau 1 site (residues 191-225) and the most carboxyl-terminal portion of the protein (residues 386-438) carries more than two abnormal phosphates. Ser-262 was also phosphorylated in a fraction of PHF-tau. Modifications other than phosphorylation, removal of the initiator methionine, and N alpha-acetylation at the amino terminus and deamidation at 2 asparaginyl residues were found in PHF-tau, but these modifications were also present in normal tau.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512244

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  103 in total

1.  Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons.

Authors:  S E Merrick; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Genetic modifiers of tauopathy in Drosophila.

Authors:  Joshua M Shulman; Mel B Feany
Journal:  Genetics       Date:  2003-11       Impact factor: 4.562

3.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

4.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

Review 5.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 6.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

7.  Comparison of the phosphorylation of microtubule-associated protein tau by non-proline dependent protein kinases.

Authors:  T J Singh; I Grundke-Iqbal; B McDonald; K Iqbal
Journal:  Mol Cell Biochem       Date:  1994-02-23       Impact factor: 3.396

8.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

9.  Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP.

Authors:  L M Fleming; G V Johnson
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

Review 10.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.